The vaccine candidate sponsored by the University of Oxford and AstraZeneca has shown promise in preventing COVID-19 in Phase III clinical trials, but the evidence is not yet convincing enough to put it in the same category as competitors from Pfizer-BioNTech and Moderna. Consequently, it is likely that the Food and Drug Administration (FDA) will insist on more and better data before granting regulatory approval.
Want to see more of The Dispatch in Google search?
Add Us as a Preferred Source



